Behavioral modifications like goal setting could lead to greater weight loss on tirzepatide

Article excerpt

A major real-world study of GLP-1 medications presented at the Endocrine Society's annual meeting found that behavioral factors, particularly setting weight-loss goals beforehand, predicted the greatest weight loss alongside demographic factors. Women, people without pre-existing conditions like type 2 diabetes or high blood pressure, and those who had previously committed to a specific weight target saw the most success on tirzepatide. The findings suggest that combining medication with goal-setting practices could optimize outcomes for patients seeking weight loss.